{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:13:00Z","timestamp":1777479180734,"version":"3.51.4"},"reference-count":40,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007788","name":"Blood Disease Research Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100007788","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helsinki University Hospital grant for Coagulation Medicine","award":["TYH2024310"],"award-info":[{"award-number":["TYH2024310"]}]},{"name":"Pulsus Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Finnish Government Subsidy for Health Science Research","award":["TYH2023238"],"award-info":[{"award-number":["TYH2023238"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Convalescent plasma (CP) therapy for COVID-19 infection may have favorable safety but varying efficacy, with concerns about its procoagulant impact. We investigated whether administration of CP to hospitalized patients affects their coagulation profile. Fifty-four patients randomized in a double-blinded fashion received either placebo, low-titer CP (LCP) or high-titer CP (HCP). Donor blood samples were obtained at the time of the plasmapheresis, while recipient blood samples were collected before infusion, one day post-infusion and between two and six days after infusion. Routine laboratory follow-up, coagulation biomarkers, antiphospholipid antibodies, and thrombin generation (TG) were assessed. CP donors had normal blood cell counts and coagulation profiles, without differences between LCP and HCP donors at the baseline. All CP recipients were on low-molecular-weight heparin thromboprophylaxis at the time of the infusion. Despite randomization, the HCP group had lower baseline (p\u2009=\u20090.004) and Day 1 platelet counts (p\u2009=\u20090.019) than the LCP group. Von Willebrand antigen (VWF:Ag) levels clearly exceeded normal without differences at baseline. At Day 1, LCP recipients had higher VWF:Ag (mean\u2009\u00b1\u2009SD 224\u2009\u00b1\u200915%) than HCP recipients (210\u2009\u00b1\u20098%) (p\u2009=\u20090.012). In all groups, overall 80% lupus anticoagulant was positive. Baseline TG variables were comparable, but again LCP recipients exhibited higher endogenous thrombin potential (ETP) (1313\u2009\u00b1\u2009535 nM.min) (p\u2009=\u20090.038) and peak TG (184\u2009\u00b1\u2009106 nM) (p\u2009=\u20090.037) than the HCP group (870\u2009\u00b1\u2009425 nM.min and 86\u2009\u00b1\u200954 nM). Our findings show that LCP increases VWF:Ag levels and enhances TG despite the thromboprophylaxis. These results suggest that HCP induces less hypercoagulability than LCP, which may contribute to the variability in CP efficacy.<\/jats:p>","DOI":"10.1177\/10760296251317522","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T06:08:41Z","timestamp":1738303721000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Coagulation Profile of Convalescent Plasma Donors and Recipients"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2259-3244","authenticated-orcid":false,"given":"Hanna H","family":"Pitk\u00e4nen","sequence":"first","affiliation":[{"name":"Helsinki University Hospital, Division of Anesthesiology, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Department of Hematology, Coagulation Disorders Unit, Helsinki University Hospital, Helsinki, Finland"},{"name":"Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuukka","family":"Helin","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, HUS Diagnostic Centre, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamim","family":"Khawaja","sequence":"additional","affiliation":[{"name":"Meilahti Vaccine Research Center, MeVac, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Department of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"FIMAR, Multidisciplinary Center of Excellence in Antimicrobial Resistance Research, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka-Pekka","family":"Pietil\u00e4","sequence":"additional","affiliation":[{"name":"Meilahti Vaccine Research Center, MeVac, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"FIMAR, Multidisciplinary Center of Excellence in Antimicrobial Resistance Research, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Kajova","sequence":"additional","affiliation":[{"name":"Meilahti Vaccine Research Center, MeVac, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Department of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"FIMAR, Multidisciplinary Center of Excellence in Antimicrobial Resistance Research, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"V\u00e4limaa","sequence":"additional","affiliation":[{"name":"Meilahti Vaccine Research Center, MeVac, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Department of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tero","family":"Vahlberg","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Turku and Turku University Hospital, Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarkko","family":"Ihalainen","sequence":"additional","affiliation":[{"name":"Finnish Red Cross Blood Service, Vantaa, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Vierikko","sequence":"additional","affiliation":[{"name":"Finnish Medicines Agency, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olli","family":"Vapalahti","sequence":"additional","affiliation":[{"name":"Viral Zoonoses Research Unit, Departments of Virology and Veterinary Biosciences, University of Helsinki and Helsinki University Hospital Diagnostic Center, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Kantele","sequence":"additional","affiliation":[{"name":"Meilahti Vaccine Research Center, MeVac, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Department of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"},{"name":"Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"FIMAR, Multidisciplinary Center of Excellence in Antimicrobial Resistance Research, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[{"name":"Department of Hematology, Coagulation Disorders Unit, Helsinki University Hospital, Helsinki, Finland"},{"name":"Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"bibr1-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138003"},{"key":"bibr2-10760296251317522","unstructured":"Recommendations for Investigational COVID-19 Convalescent Plasma | FDA [Internet]. [cited 2024 Nov 19]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-applications-inds-cber-regulated-products\/recommendations-investigational-covid-19-convalescent-plasma."},{"key":"bibr3-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140200"},{"key":"bibr4-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.10.035"},{"key":"bibr5-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.10.036"},{"issue":"2","key":"bibr6-10760296251317522","first-page":"1","volume":"2023","author":"Iannizzi C","journal-title":"Cochrane Database Syst Rev [Internet]"},{"key":"bibr7-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033700"},{"key":"bibr8-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119657"},{"key":"bibr9-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10044"},{"key":"bibr10-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01488-2"},{"key":"bibr11-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00545-2"},{"issue":"1","key":"bibr12-10760296251317522","first-page":"1","volume":"12","author":"Gharbharan A","journal-title":"Nat Commun [Internet]"},{"issue":"1","key":"bibr13-10760296251317522","first-page":"1","volume":"12","author":"Thorlacius-Ussing L","journal-title":"Sci Rep [Internet]"},{"issue":"1","key":"bibr14-10760296251317522","first-page":"1","volume":"12","author":"van den Berg K","journal-title":"Sci Rep [Internet]"},{"key":"bibr15-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209502"},{"key":"bibr16-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012248"},{"issue":"6","key":"bibr17-10760296251317522","first-page":"423","volume":"56","author":"Khawaja T","journal-title":"Infect Dis (Auckl) [Internet]"},{"key":"bibr18-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7"},{"key":"bibr19-10760296251317522","unstructured":"Brecher ME. European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS) [Internet]. 2017. http:\/\/www.eqas.ir\/pdf\/lib\/AABB Technical Manual 15TH.pdf."},{"key":"bibr20-10760296251317522","volume-title":"Guide to the Preparation, Use and Quality Assurance of Blood Components","author":"European Directorate for the Quality of Medicines &amp;HealthCare (EDQM)","year":"2020","edition":"20"},{"key":"bibr21-10760296251317522","volume-title":"An EU Pro-gramme of COVID-19 Convalescent Plasma Collection and Transfusion: Guidance on Collection, Testing, Processing, INFECTIOUS DISEASES 431storage, Distribution and Monitored Use","author":"Directorate-General for Health and Food Safety","year":"2020"},{"key":"bibr22-10760296251317522","unstructured":"EUROPEAN COMMISSION. Guidance on the collection and transfusion of convalescent COVID-19 plasma | Public Health [Internet]. 2020 [cited 2024 Nov 27]. https:\/\/health.ec.europa.eu\/latest-updates\/guidance-collection-and-transfusion-convalescent-covid-19-plasma-2020-04-10_en."},{"key":"bibr23-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15047"},{"issue":"5","key":"bibr24-10760296251317522","volume":"24","author":"Pitk\u00e4nen HH","journal-title":"Haemophilia [Internet]"},{"key":"bibr25-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15409"},{"key":"bibr26-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12676"},{"key":"bibr27-10760296251317522","unstructured":"FDA. Fact sheet for health care providers: emergency use authorization (EUA) of COVID-19 convalescent plasma for treatment of hospitalized patients with COVID-19, 2021. Accessed November 28, 2024. https:\/\/www.fda.gov\/media\/141478\/download."},{"key":"bibr28-10760296251317522","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.262634"},{"key":"bibr29-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15191"},{"key":"bibr30-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00695-1"},{"key":"bibr31-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.06.008"},{"key":"bibr32-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.07.020"},{"key":"bibr33-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1002\/art.41777"},{"key":"bibr34-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1242723"},{"key":"bibr35-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15808"},{"key":"bibr36-10760296251317522","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep15020024"},{"key":"bibr37-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02475-7"},{"key":"bibr38-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00223-7"},{"key":"bibr39-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215383"},{"key":"bibr40-10760296251317522","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.10.020"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251317522","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296251317522","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251317522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:03Z","timestamp":1777385103000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296251317522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"alternative-id":["10.1177\/10760296251317522"],"URL":"https:\/\/doi.org\/10.1177\/10760296251317522","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"10760296251317522"}}